Introduction
We recently reported that neutrophils are sufficient to induce active systemic anaphylaxis (ASA) in mice. 1 Not only mouse neutrophils, but also human neutrophils, could indeed restore ASA when transferred into mice that are resistant to ASA because they lack activating IgG receptors (Fc␥R). Mouse neutrophils express 2 Fc␥Rs, Fc␥RIIIA and Fc␥RIV, which accounted for ASA induction. 1 However, human neutrophils express neither Fc␥RIIIA nor Fc␥RIV. They express 2 other Fc␥Rs, Fc␥RIIA and Fc␥RIIIB, which do not exist in mice. 2 Noticeably, Fc␥RIIA, but not Fc␥RIIIB, can bind mouse IgG. 1 Fc␥RIIA may therefore be responsible for inducing human neutrophil activation when transferred into ASA-resistant mice.
Anaphylaxis is a systemic hyperacute allergic reaction that develops within minutes after antigen/allergen exposure in humans. It can be reproduced experimentally by injecting antigen in animals immunized with the same antigen (active anaphylaxis), or in mice preinjected with antigen-specific IgE or IgG antibodies (passive anaphylaxis). Not only systemic anaphylaxis leading to hypothermia, hypotension, and respiratory distress, but also local anaphylaxis leading to extravasation and inflammation, can be induced in mice depending on the route used for antigen challenge. Different models were found to depend on different mechanisms. IgE-induced and IgG1-induced passive cutaneous anaphylaxis (PCA) required mast cells. 3, 4 IgE-induced passive systemic anaphylaxis (PSA) also required mast cells. 5, 6 However, IgG1-induced PSA was reported to require basophils, 7 whereas IgG2-induced PSA required neutrophils. 1 Mast cells 5 and basophils 7, 8 were not required for ASA that depended on monocytes/macrophages, 9 or on neutrophils 1 depending on the experimental model. Therefore, each of these 4 cell types contribute to a specific model of anaphylaxis, but their respective contribution in humans remains to be determined.
In mice, mast cells, basophils, neutrophils, and monocytes/ macrophages express activating FcRs that require the association of the ITAM-containing FcR␥-subunit to be expressed and functional at the cell membrane. Importantly, FcR␥ Ϫ/Ϫ mice developed neither PCA, nor PSA or ASA, indicating that activating FcRs are mandatory for the induction of these reactions. Mast cells and basophils express specifically the murine high-affinity IgE receptor Fc⑀RI, and neutrophils and monocytes/macrophages express specifically the murine high-affinity IgG receptor Fc␥RIV. 10 However, all of these cells express the low-affinity IgG receptor Fc␥RIIIA. Passive anaphylaxis models have demonstrated that Fc⑀RI is mandatory for IgE-induced PCA and PSA, 11 Fc␥RIIIA for IgG1induced PCA 12 and PSA, 6 and Fc␥RIV for IgG2-induced PSA. 1 Fc␥RIIIA and Fc␥RIV, 1 but not Fc⑀RI, 6 contributed detectably to ASA models.
Human neutrophils do not express Fc␥RIIIA, and Fc␥RIV does not exist in humans. 10 Instead human neutrophils express the low-affinity activating IgG receptor Fc␥RIIA. Fc␥RIIA possesses its own ITAM in its intracytoplasmic domain, and is not associated with the FcR␥-subunit. 2 The Fc␥RIIA ITAM, however, is noncanonical and has been described to be less potent in inducing cell activation in vitro than the FcR␥ ITAM. 13, 14 Fc␥RIIA binds all 4 human IgG subclasses, 15 as well as mouse IgG1, IgG2a, and IgG2b subclasses. 1 Polymorphisms in the gene encoding Fc␥RIIA have been reported to be linked to bronchial asthma and allergic rhinitis, 16 suggesting a role for Fc␥RIIA in allergic reactions. Mice transgenic for the Fcgr2a gene have been generated that recapitulate the expression of Fc␥RIIA in humans. 17 These Fc␥RIIA tg mice spontaneously developed autoimmune diseases on a wild-type (WT) background (ie, pneumonitis, glomerulonephritis, and rheumatoid arthritis). 18 Fc␥RIIA, expressed on the FcR␥ Ϫ/Ϫ background, was sufficient to induce experimental models of thrombocytopenia 19 and rheumatoid arthritis. 20 The ability of Fc␥RIIA to induce allergic reactions has not been investigated.
Fc␥RIIA is the most widely expressed FcR in humans, 18 and remarkably the only activating IgG receptor constitutively expressed by mast cells, basophils, neutrophils, and eosinophils. Mast cells, basophils, and eosinophils are well-known effectors of allergic reactions, and our recent work suggests that neutrophils might be effectors of anaphylaxis. 1 We therefore studied the ability of human Fc␥RIIA to induce passive and active anaphylaxis, and models of allergic inflammation in skin and airways. To this aim, we used Fc␥RIIA-transgenic mice on backgrounds deficient for endogenous FcRs. We found that Fc␥RIIA was sufficient to induce mast cell and macrophage activation in vitro, and mast celldependent PCA and lung inflammation in vivo. Fc␥RIIA-induced PSA was dependent on monocytes/macrophages and neutrophils, but not on mast cells and basophils. Noticeably, Fc␥RIIA was sufficient to induce fatal ASA. Finally, human mast cells, monocytes, and neutrophils produced anaphylactogenic mediators after Fc␥RIIA engagement. Fc␥RIIA may therefore be the major activating IgG receptor contributing to allergic reactions and anaphylaxis in humans.
Methods

Mice
C57BL/6J Fc␥RIIA tg mice were provided by M. P. Reilly (Jefferson Medical College, Philadelphia, PA), Fc␥RI/IIB/IIIA triple-deficient (3KO) mice (N6 C57BL/6J) by S. Verbeek (Leiden University Medical Center, Leiden, The Netherlands), KRN tg mice by D. Mathis and C. Benoist (Harvard Medical School, Boston, MA) and IGBMC (Strasbourg, France). WT C57BL/6J mice were purchased from Charles River, W sh /W sh and FcR␥ Ϫ/Ϫ C57BL/6J mice from The Jackson Laboratory. Fc␥RI/IIB/IIIA Ϫ/Ϫ Fc⑀RI Ϫ/Ϫ Fc⑀RII Ϫ/Ϫ (5KO; N6 C57BL/6J) mice were previously described. 21 Fc␥RIIA tg mice were intercrossed with 3KO, 5KO, FcR␥ Ϫ/Ϫ , and/or W sh /W sh mice to obtain 3KOIIA, 5KOIIA, FcR␥ Ϫ/Ϫ IIA, and W sh 3KOIIA-transgenic mice, respectively. All mice carrying the hFc␥RIIA transgene were used as heterozygous animals. Nontransgenic littermates served as controls. Mice in all experiments were 6-10 weeks old. All mouse protocols were approved by the Animal Care and Use Committees of Paris, Ile de France, France.
Active systemic anaphylaxis
Mice were injected intraperitoneally on day 0 with 200 g BSA, either in CFA or in alum, and boosted intraperitoneally on day 14 with 200 g BSA in IFA or in alum, respectively. BSA-specific IgG1 and IgG2a/b/c antibodies in serum were titered by ELISA on day 17 as described. 1 Mice with comparable antibody titers were challenged intravenously with 500 g BSA, 8 days after the last immunization. Central temperature was monitored using a digital thermometer (YSI).
Passive systemic anaphylaxis
Immune complexes made of 1 mg OVA and 1 mg anti-OVA mAb (clone OVA-14), or 20 L K/BxN serum and 50 g GPI in 200 L physiologic solution were preformed at 37°C and injected intravenously. Alternatively, 50 or 150 g of mAb IV.3 were injected intravenously. Central body temperature was recorded.
Passive cutaneous anaphylaxis
ICs were preformed by incubating OVA and OVA-14 in a 1:1 ratio for 15 minutes at 37°C. Indicated amounts of these ICs, or heat-aggregated (1 hour at 63°C) purified human IgG or anti-Fc␥RIIA mAb IV.3 were injected intradermally in 20 L total volume, immediately followed by an intravenous (IV) injection of 100 L PBS containing 2% Evans Blue. Thirty minutes later, Evans blue was extracted from 1-cm-diameter skin pieces using formamide at 63°C and quantified by absorbance (620 nm).
Airway inflammation
Mice were injected intranasally with 50 L of rabbit anti-OVA antiserum and 500 g of OVA intravenously. After indicated periods of time, mice were lethally anesthetized, and 4 broncho-alveolar lavages of, respectively, 0.5, 1, 1, and 1 mL PBS were performed. The supernatant of the first lavage was used to quantify MPO and keratinocyte-derived chemokine (KC) content. The cells from all lavages were pooled for cell count analysis. Hemorrhage score was determined on pooled lavages and ranged from 0 (no blood present), 1 (detectable hemorrhage), to 3 (strong hemorrhage).
Alveolar macrophages, recovered by 3 consecutive 1 mL bronchoalveolar lavages from individual mice, were exposed for 3 hours to 3 different conditions: (1) no stimulant, (2) plate-bound ICs made of 100 g/mL OVA and 30 g/mL rabbit anti-OVA, and (3) plate-bound anti-Fc␥RIIA mAbs (100 g/mL). Supernatants were assayed for KC and MIP-1␣ by ELISA (R&D Systems).
In vivo blocking and depletion
Anti-Fc␥RIIA mAb (50 g/mouse) was injected intravenously either once (24 hours), or twice (24 hours and 12 hours) before the experiment. 300 L/mouse PBS-or clodronate-liposomes (at 7 mg/mL), 300 g/mouse anti-Gr1, 300 g/mouse anti-Ly-6G, 10 g/mouse anti-CD200R3 mAbs, or 1 mg/mouse GdCl 3 were injected 24 hours before the experiment. Depletion of specific populations was ascertained using flow cytometry on blood samples taken during or after the experiment (examples are shown in supplemental Figure 3B -E, available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
Please refer to supplemental Methods for information on antibodies, reagents, and cells; flow cytometry analysis; lung histology; statistical analyses; and in vitro cell activation.
Results
Fc␥RIIA can trigger active systemic anaphylaxis
Active systemic anaphylaxis was induced by an IV antigen challenge in mice immunized with the same antigen. This protocol induced a body temperature decrease and mortality in WT mice, but not in FcR␥ Ϫ/Ϫ mice, immunized with antigen in Alum (supplemental Figure 1A ) or in Freund adjuvant (supplemental Figure 1B ). Immunizations in either adjuvant lead to the production of IgG1 and IgE antibodies, but only immunizations in Freunds adjuvant lead to the production of IgG2 antibodies in both mouse strains (data not shown). Human neutrophils express both Fc␥RIIA and Fc␥RIIIB ( Figure 1A ), but only Fc␥RIIA and not Fc␥RIIIB can bind mouse IgG ( Figure 1B) . To analyze the capacity of Fc␥RIIA to induce ASA, we developed transgenic mouse models expressing human Fc␥RIIA under the control of its own promoter, and deficient for endogenous FcRs. Fc␥RIIA tg mice express Fc␥RIIA not only on neutrophils, but also on eosinophils, monocytes, macrophages, and weakly on basophils ( Figure 1C ). Fc␥RIIA tg mice therefore reproduce the expression pattern found in humans ( Figure 1D ). Noticeably, whereas human neutrophils and basophils express Fc␥RIIA (supplemental Figure 1C ), mouse neutrophils express Fc␥RIIIA and Fc␥RIV, and mouse basophils only Fc␥RIIIA, 1 as ITAM-bearing activating Fc␥R.
After antigen challenge, ASA developed in FcR␥ Ϫ/Ϫ IIA mice, but not in nontransgenic FcR␥ Ϫ/Ϫ littermates, immunized with antigen in Freunds adjuvant ( Figure 1E ) or in Alum ( Figure 1F ) leading to a severe temperature drop and 100% mortality. IV injections of anti-Fc␥RIIA blocking mAbs abolished ASA-induced temperature drop and mortality in FcR␥ Ϫ/Ϫ IIA mice immunized in Freunds adjuvant (data not shown) or in Alum ( Figure 1G ). Fc␥RIIA is therefore sufficient to trigger fatal active systemic anaphylaxis.
Fc␥RIIA can trigger passive systemic anaphylaxis
To investigate the potential of Fc␥RIIA to induce PSA, we used divalent (anti-Fc␥RIIA mAbs) or multivalent (IgG-immune complexes) ligands. An IV injection of 150 g, but not of 50 g, anti-Fc␥RIIA mAb IV.3 induced a modest temperature drop in FcR␥ Ϫ/Ϫ IIA mice, but not in FcR␥ Ϫ/Ϫ mice (Figure 2A ). Noticeably, FcR␥ Ϫ/Ϫ mice lack all activating Fc␥Rs but express inhibitory Fc␥RIIB, which has been reported to negatively regulate PSA induced by mouse-activating Fc␥Rs. 22 Fc␥RIIB binds, like human Fc␥RIIA, mouse IgG1 and IgG2 subclasses. IgG-immune complexes may therefore coaggregate human Fc␥RIIA with mouse Fc␥RIIB, leading to the inhibition of Fc␥RIIA-dependent activation, 23 and consequently of Fc␥RIIAinduced PSA. We therefore crossed Fc␥RIIA tg mice to Fc␥RI/ Fc␥RIIB/Fc␥RIIIA Ϫ/Ϫ (3KO) mice or to Fc␥RI/Fc␥RIIB/ Fc␥RIIIA Ϫ/Ϫ Fc⑀RI/Fc⑀RII Ϫ/Ϫ (5KO) mice ( Figure 2B ). 3KO and 5KO mice lack all IgG receptors except the activating IgG2 receptor Fc␥RIV, 21 whereas FcR␥ Ϫ/Ϫ mice lack all IgG receptors except the inhibitory IgG1/IgG2 receptor Fc␥RIIB. An injection of 150 g mAb IV.3 induced a significant temperature drop in 3KOIIA mice ( Figure 2C ) and in 5KOIIA mice ( Figure  2D ). Because 50 g mAb IV.3 induced no or a very weak temperature drop, we used this dose to block Fc␥RIIA in 3KOIIA and 5KOIIA mice.
Likewise, an IV injection of monoclonal IgG1-( Figure 2E ) or polyclonal IgG-immune complexes ( Figure 2F ) induced a significant temperature drop in 3KOIIA mice, but not in 3KO mice. Pretreatment with anti-Fc␥RIIA mAb IV.3 abolished these temperature drops in 3KOIIA mice (Figure 2E -F bottom panels). Fc␥RIIA is therefore sufficient to trigger monoclonal IgG1-induced PSA and polyclonal IgG-induced PSA.
Neutrophils and monocytes/macrophages mediate Fc␥RIIA-dependent PSA
All cell types that express Fc␥RIIA, ie, neutrophils, monocytes/ macrophages, basophils, and eosinophils ( Figure 1C ) can potentially contribute to PSA. We found recently that neutrophils are responsible for polyclonal IgG-IC-induced PSA, 1 whereas basophils were reported to be responsible for monoclonal IgG1-IC-induced PSA. 7 Polyclonal IgG-IC-induced PSA was reduced by neutrophil depletion after injection of anti-Gr1 ( Figure 3A ) or anti-Ly-6G ( Figure 3B ) mAbs in 3KOIIA mice. Neutrophils therefore contribute to Fc␥RIIA-dependent PSA. Surprisingly, basophil depletion did not affect PSA ( Figure 3C ). To investigate whether Fc␥RIIA-triggered PSA depends on mast cells, 3KOIIA mice, and as negative controls 3KO mice were crossed with W sh /W sh mice. W sh 3KOIIA mice developed unaltered Fc␥RIIAtriggered PSA, that is, in the absence of mast cells ( Figure 3D ).
However, depletion of monocytes/macrophages induced by toxic liposomes, but not by control liposomes, reduced PSA ( Figure 3E ). Supporting this result, PSA was reduced in 3KOIIA mice injected with gadolinium, which inhibits monocytes/macrophage function ( Figure  3F ). Monocytes/macrophages therefore also contribute to Fc␥RIIAdependent PSA. Depletion of a single cell population reduced PSA, but depletion of both neutrophils and monocytes/macrophages abrogated PSA in 3KOIIA mice ( Figure 3G ). In line with these results, monocytes/macrophage depletion and neutrophil depletion also inhibited anti-Fc␥RIIA mAb-induced PSA ( Figure 3H ). Collectively, these data demonstrate that neutrophils and monocytes/ macrophages, together, account for Fc␥RIIA-dependent passive systemic anaphylaxis.
To investigate if neutrophils and monocytes may also contribute to anaphylactic reactions in humans, we investigated whether these Fc␥RIIA-expressing cell types produce anaphylactogenic mediators after Fc␥RIIA engagement. Monocytes and neutrophils purified from the blood of normal donors could be activated in vitro by anti-Fc␥RIIA mAb-or human IgG-heat aggregates, as revealed by their decreased CD62L expression ( Figure 4A ). In the same conditions, both human monocytes and human neutrophils produced platelet activating factor (PAF; Figure 4B ), 24 whereas monocytes, but not neutrophils, produced leukotriene B 4 (LTB 4 ; Figure 4C ) and LTC 4 ( Figure 4D ). Human monocytes and neutrophils therefore produce anaphylactogenic mediators (ie, PAF and leukotrienes) after Fc␥RIIA engagement, supporting a role for Fc␥RIIA in human allergic reactions. 
Fc␥RIIA triggers mast cell-dependent passive cutaneous anaphylaxis
Mast cells are responsible for IgE-induced PSA 6 and for PCA. 25 IgG1-induced PCA, which depends on mouse Fc␥RIIIA, was also reported to depend on mast cells using mast cell-deficient W/W v or W sh /W sh mice. 26 Mast cells may also be responsible for cutaneous anaphylaxis in humans because degranulated mast cells are found in skin biopsies from allergic patients, and because mast cellspecific mediator levels correlate with the severity of allergic skin inflammation. As human mast cells express Fc␥RIIA, 27 we investigated whether Fc␥RIIA could trigger IgG-induced PCA. Intradermal injections of increasing doses of IgG1-IC (supplemental Figure  2A) or of mAb IV.3 (supplemental Figure 2B ) induced cutaneous anaphylaxis in 5KOIIA mice, but not in 5KO mice, as assessed by Evans blue extravasation. Intradermal injections of IgG1-IC, but not of antigen or Ab alone, induced PCA in 5KOIIA mice that was inhibited by an IV pretreatment with anti-Fc␥RIIA mAb ( Figure  5A , supplemental Figure 2C ). Similarly, intradermal injections of heat-aggregated (HA) human polyclonal IgG induced cutaneous reactions in 5KOIIA mice, but not in 5KO mice, that were abolished by anti-Fc␥RIIA mAb pretreatment ( Figure 5B , supplemental Figure 2D ). Fc␥RIIA can therefore trigger mouse and human IgG-induced PCA.
Mouse IgG1-induced Fc␥RIIIA-dependent PCA is abrogated in W/W v4 and W sh /W sh mice (data not shown). We investigated whether Fc␥RIIA-triggered PCA also depends on mast cells by comparing 3KOIIA mice with W sh 3KOIIA mice. As expected, 3KOIIA mice developed mouse IgG1-induced PCA. W sh 3KOIIA mice, however, as well as W sh 3KO mice used as negative controls, were protected from mouse IgG1-induced PCA ( Figure 5C , supplemental Figure 3E ). Mast cells are therefore mandatory for Fc␥RIIA-triggered IgG-induced PCA.
Fc␥RIIA aggregation induces mast cell degranulation in vitro and ex vivo
Because IgG-induced mast cell-dependent PCA occurs in 3KOIIA mice, mast cells are expected to express Fc␥RIIA. Ex vivo peritoneal mast cells from 3KOIIA mice indeed express Fc␥RIIA ( Figure 5D ), but no other Fc␥R (not shown). IgG-IC induced ex vivo peritoneal mast cells from 3KOIIA mice, but not from 3KO mice to degranulate ( Figure 5E ) and release histamine ( Figure 5F ). Anti-IgE antibodies, however, induced IgE-bearing peritoneal mast cells from both naive strains to degranulate and release histamine. Fc␥RIIA aggregation can therefore activate mast cells.
Like peritoneal mast cells from 3KOIIA mice, in vitro cultured peritoneal cell-derived mast cells (PCMCs), 28 fetal skin-derived mast cells (FSMCs), and bone marrow-derived mast cells (BM-MCs) from the same mice all expressed Fc␥RIIA ( Figure 6A ). PCMCs from 3KOIIA mice, but not from 3KO mice, bound monoclonal IgG1-IC and polyclonal IgG-IC ( Figure 6B ). Incubation of 3KOIIA PCMCs with either of these immune complexes induced mast-cell activation as revealed by Ca 2ϩ fluxes ( Figure 6C ) and intracellular protein phosphorylation ( Figure 6D ). Fc␥RIIA aggregation by IgG-IC induced consistent syk, PLC␥1, Akt, IB, and ERK1/2 phosphorylation, but a barely detectable LAT phosphorylation compared with that induced by the aggregation of Fc⑀RI by IgE plus antigen on the same cells ( Figure 6D ). Fc␥RIIA aggregation, similar to Fc⑀RI aggregation, induced a sustained phosphorylation of SHIP1, as previously reported in monocytes. 29 This SH2-containing inositol-5-phosphatase negatively regulates signaling by FcR␥-chain associated FcRs, and is mandatory for Fc␥RIIBdependent negative regulation of mast cell activation. 30, 31 Fc␥RIIA aggregation also induced PCMC degranulation, as revealed by ␤-hexosaminidase and histamine release ( Figure 6E ), supporting our results obtained with ex vivo peritoneal mast cells ( Figure 5E-F ). In addition, Fc␥RIIA aggregation induced lipid mediator production, that is, LTC 4 and prostaglandin D 2 (PGD 2 ) by PCMCs ( Figure 6F ). Thus, IgG-immune complexes induced Fc␥RIIA-triggered activation of mast cells leading to the release of mediators involved in vascular permeability (eg, histamine, LTC 4 , PGD 2 ), which is consistent with Fc␥RIIA's ability to induce PCA.
We therefore analyzed the expression of Fc receptors on human skin-derived mast cells (SMC), and the ability of Fc␥RIIA to induce human skin mast cell activation. Human SMC constitutively express the high-affinity IgE receptor Fc⑀RI, as expected, and a single IgG receptor, Fc␥RIIA ( Figure 6G ), as described. 27 Fc␥RIIA aggregation by anti-Fc␥RIIA mAb induced ␤-hexosaminidase and histamine release by human SMC (Figure 6H ). Fc⑀RI aggregation was used as a positive control. Fc␥RIIA is therefore sufficient to activate human mast cells, and may be involved in the induction of mast cell-dependent inflammation and allergic reactions in humans.
Fc␥RIIA enables passive airway inflammation
Constriction of smooth muscles and subsequent granulocyte infiltration in the airways during asthmatic inflammation is thought to result from histamine and leukotriene release from mast cells after allergen inhalation. Thus, we wondered whether Fc␥RIIA may induce airway inflammation as it is expressed on mast cells and granulocytes. Fc␥RIIA is expressed in human lung tissue ( Figure   7A ), but also in lung sections ( Figure 7B ), and on alveolar macrophages ( Figure 7C ) from 3KOIIA mice. Unlike human asthma, most asthma models in mice are independent of antibody production by B cells, 32, 33 and consequently do not require FcRs. We therefore used a model of airway inflammation that depends on IgG and on Fc␥Rs, 34 and that consists of an IV injection of OVA and of an intranasal injection of anti-OVA rabbit serum, presumably forming ICs in vivo. Preformed OVA-anti-OVA rabbit serum ICs could bind to CHO cells expressing Fc␥RIIA, but not to untransfected CHO cells ( Figure 7D ). CD11c ϩ /Gr1 Ϫ alveolar macrophages represent more than 90% of the cells present in the alveolar space, as detected in broncho-alveolar lavages (BAL) of FcR␥ Ϫ/Ϫ , FcR␥ Ϫ/Ϫ IIA, and WT mice ( Figure 7E ). Concomitant intranasal instillation of anti-OVA rabbit serum and intravenous injection of OVA induced a massive infiltration of CD11c Ϫ /Gr1 ϩ cells (Ͼ 80% of BAL content) in WT and in FcR␥ Ϫ/Ϫ IIA mice, but not in FcR␥ Ϫ/Ϫ mice (ϳ 5% CD11c Ϫ /Gr1 ϩ granulocytes; Figure  7F ). Fc␥RIIA therefore induces granulocytes recruitment to the lung, and can replace endogenous FcR␥-associated activating FcRs. Total cell numbers in the BAL were unchanged at t ϭ 3 hours after challenge, but increased starting t ϭ 6 hours and reached 5 times the background value at t ϭ 16 hours in FcR␥ Ϫ/Ϫ IIA mice, but not in FcR␥ Ϫ/Ϫ mice ( Figure 7G ). Granulocyte numbers in BAL represented most of this increase, whereas alveolar macrophage numbers did not vary statistically along the time course. Myeloperoxidase, which is mainly produced by neutrophils and by inflammatory macrophages in vivo, 35, 36 was detected at t ϭ 16 hours postchallenge in FcR␥ Ϫ/Ϫ IIA mice, but not in FcR␥ Ϫ/Ϫ mice. ( Figure  7H ). Similar results were obtained when analyzing the hemorrhage score that reflects lung tissue damage ( Figure 7I ). KC, a chemokine produced by macrophages that can attract neutrophils to the site of inflammation, was found in BAL fluid of FcR␥ Ϫ/Ϫ IIA and to a lesser extent in FcR␥ Ϫ/Ϫ mice, as early as 3 hours after inoculation of antibody and antigen ( Figure 7J ). This result suggests that alveolar macrophages are activated after Fc␥RIIA aggregation by IgG-immune complexes, and release KC before neutrophil accumulation in the broncho-alveolar space, in agreement with the dependency on alveolar macrophages reported for this disease model. 37 Supporting this hypothesis, purified alveolar macrophages from FcR␥ Ϫ/Ϫ IIA mice, but not from FcR␥ Ϫ/Ϫ mice, secreted KC ex vivo after IgG-IC or anti-Fc␥RIIA mAb stimulation ( Figure 7K ). Similar results were obtained when analyzing MIP-1␣ secretion ( Figure 7L ), suggesting that Fc␥RIIA-triggered alveolar macrophages contribute to chemokine-induced granulocyte recruitment to the lung. Fc␥RIIA can therefore induce airway inflammation characterized by granulocyte infiltration in a passive antibody-dependent mouse model.
Discussion
In this report, we provide evidence that human Fc␥RIIA contributes to IgG-mediated allergic reactions. Indeed, we demonstrate here for the first time that human Fc␥RIIA is sufficient to induce active and passive systemic anaphylaxis, cutaneous anaphylaxis, and lung inflammation in Fc␥RIIA-transgenic mice. Mast cells could be activated upon Fc␥RIIA engagement in vitro and were necessary for Fc␥RIIA-dependent PCA. Neither mast cells nor basophils, however, were mandatory for Fc␥RIIA-dependent PSA, which was induced by neutrophils and monocytes/macrophages. Finally, targeting Fc␥RIIA with specific blocking mAbs abolished passive and active anaphylaxis.
Human Fc␥RIIA has been described to contribute to several models of autoimmune diseases and inflammatory reactions in transgenic mice. When expressed on a WT background, ie, as an additional activating IgG receptor, Fc␥RIIA was reported to increase the severity of experimental thrombocytopenia, 17 and to increase the incidence of autoimmune arthritis, pneumonitis, and glomerulonephritis at older age. 18 These reports suggested that Fc␥RIIA may also induce inflammatory diseases in the absence of other FcRs. Indeed, when expressed on a mouse FcR␥ Ϫ/Ϫ background, that is, in the absence of other activating IgG receptors, Fc␥RIIA was reported to induce experimental thrombocytopenia 17 and hemolytic anaemia, 38 rheumatoid arthritis, 39 nephritis, and Arthus reaction. 40 Along the same line, we show here that Fc␥RIIA induced IgG-dependent airway inflammation when expressed in FcR␥ Ϫ/Ϫ mice. Inflammation was characterized by neutrophil infiltration of the broncho-alveolar space after KC (and MIP-1␣) secretion, probably by Fc␥RIIA-triggered alveolar macrophages. In this passive model of airway inflammation, we also observed a trend toward increased metacholine-induced bronchial resistance as measured by plethysmography, in FcR␥ Ϫ/Ϫ IIA but not FcR␥ Ϫ/Ϫ mice (data not shown). In addition to its contribution to autoimmune disorders, Fc␥RIIA may therefore also contribute to allergic reactions. Polymorphisms in the gene encoding Fc␥RIIA have indeed been identified as risk factors for bronchial asthma and allergic rhinitis. 16 Further supporting a role for Fc␥RIIA in allergic reactions, we show here that Fc␥RIIA restored immediate hypersensitivity reactions in resistant mice: (1) Fc␥RIIA was indeed sufficient to induce fatal ASA following 2 different immunization protocols; (2) Fc␥RIIA engagement by intravenously injected divalent or multivalent agonists induced PSA; and (3) Fc␥RIIA induced PCA when human IgG aggregates, mouse immune complexes or anti-Fc␥RIIA mAb IV.3 were injected intradermally. Fc␥RIIA can therefore reproduce by itself in a transgenic mouse model the allergic/anaphylactic pathologies reported to be triggered by the endogenous activating mouse Fc␥Rs (Fc␥RI, Fc␥RIIIA, and Fc␥RIV), with similar severities and kinetics. Altogether these results, obtained in Fc␥RIIA-transgenic mice suggest that Fc␥RIIA might be a major player in allergic, autoimmune, and inflammatory pathologies mediated by IgG in humans.
Passive mouse models of inflammatory and allergic diseases have been reported to depend on specific cell types. Indeed, mast cells are required for PCA 3 and IgE-PSA, 5 macrophages for ITP, 41 lung inflammation 37 and passive rheumatoid arthritis, 42 basophils for IgG1-PSA, 7 and neutrophils for passive rheumatoid arthritis, 43 ASA, and polyclonal IgG-PSA. 1 All these myeloid cells express human Fc␥RIIA in transgenic mice (this paper and McKenzie et al 17 ) . Noticeably, Fc␥RIIA is the only activating (ITAM-bearing) IgG receptor expressed on these cells in humans, ie, on mast cells, neutrophils, eosinophils, and basophils. Of note, neutrophils, and to a much lower extent basophils, 44 express Fc␥RIIIB, the activating capacities of which are debated. 40, 45 As a consequence, Fc␥RIIA should be able to activate in vivo all of the cell types reported to be necessary for the induction of models of inflammatory and allergic disease in mice. Mast cells were reported to be required for mouse Fc␥RIIIA-dependent and for mouse Fc⑀RI-dependent PCA. 3, 6 We demonstrate here that mast cells are also required for human Fc␥RIIA-dependent PCA using novel mast cell-deficient Fc␥RIIAtransgenic mice. Noticeably, mast cells were also reported to be required for IgE-induced PSA (mouse Fc⑀RI-dependent), but not for IgG1-induced PSA (mouse Fc␥RIIIA-dependent). 5, 6 Although basophils were proposed to be responsible for IgG1-induced PSA, 7 basophil-deficient mice were, however, not protected. 8 We reported recently that neutrophils are required for both IgG2-induced PSA and polyclonal IgG-induced PSA. 1 Depending on the PSA model used, either mast cells, basophils, or neutrophils have therefore been reported to be mandatory for mouse FcR-dependent anaphylaxis.
We demonstrate here that neutrophils and monocytes/macrophages both contribute to Fc␥RIIA-dependent polyclonal IgG-PSA. Indeed, the depletion of both cell populations, but not of either one, was necessary to abolish the shock. Supporting these results, monocytes/macrophages and neutrophils contributed to another Fc␥RIIA-dependent PSA model, ie, when induced by IV injections of a high dose anti-Fc␥RIIA mAb. These results provide the first evidence that monocytes/macrophages contribute to a model of PSA. In agreement with IgG-induced PSA models in WT mice, 1,6 mast cells were not mandatory for Fc␥RIIA-dependent PSA. Basophils did not detectably contribute to Fc␥RIIA-dependent PSA. This latter result could be explained by the lower expression level of Fc␥RIIA on basophils than on neutrophils or monocytes/macrophages in transgenic mice, as it is in humans.
Active models of allergic diseases in mice have been reported to depend on specific cell types. Indeed, monocytes/macrophages, but not neutrophils, have been reported to be mandatory for a model of ASA performed in mice immunized with goat IgG anti-mouse IgD, and challenged with goat IgG. 9 Inversely, in a different model of ASA, performed in BSA-immunized mice challenged with BSA, we reported that neutrophils, but not monocytes/macrophages, were mandatory. 1 In addition, we could show that the transfer of human neutrophils, which express Fc␥RIIA and Fc␥RIIIB, restored ASA in resistant mice. Because Fc␥RIIA, but not Fc␥RIIIB, binds mouse IgG-immune complexes, Fc␥RIIA is probably responsible for the activation of human neutrophils in this model. We could not address the contribution of neutrophils and basophils in Fc␥RIIAdependent ASA because their depletion by specific mAbs is impaired on the FcR␥-deficient background. Indeed, whereas mouse Fc␥Rs enabled efficient cell depletion using anti-Gr1, anti-Ly-6G, or anti-CD200R3 mAbs, human Fc␥RIIA did not. All of these mAbs are of the rat IgG2b isotype that is poorly bound by human Fc␥RIIA (data not shown). Nevertheless, one may speculate that monocytes/macrophages and neutrophils also contribute to Fc␥RIIA-dependent ASA, as they contribute to Fc␥RIIAdependent PSA. Whatever the responsible cell population for Fc␥RIIA-dependent ASA, Fc␥RIIA is sufficient to promote the release of mediators leading to anaphylactic reactions. Depending on the immunization protocol, PAF was reported to be responsible, 5, 9 or to contribute partially 1 to ASA. On one hand, PAF was found to be predominant in IgG1-induced PSA 7 and we reported increased PAF levels in plasma during IgG2-induced PSA. 1 On the other hand, histamine was found mandatory for IgG-and IgEinduced PCA using histidine decarboxylase-deficient mice 46 as well as for IgE-induced PSA. 7, 47 It follows that Fc␥RIIA engagement should enable the release of PAF and/or of histamine by monocytes/macrophages, neutrophils, and mast cells. Supporting this line of reasoning, we report here that Fc␥RIIA-dependent cell activation in vitro induces human monocytes and neutrophils to produce PAF and human mast cells to release histamine. Whereas 3 to 5 times higher PAF amounts were produced by monocytes than by neutrophils, neutrophils are 10 times more numerous than monocytes in human blood, which may compensate their lower production of PAF. Intriguingly, activated monocytes but not neutrophils produced leukotrienes (ie, LTB 4 and LTC 4 ) which may also relate to anaphylaxis induction/severity in humans.
Fc␥RIIA is a nonconventional activating Fc␥R. Indeed, unlike all other activating Fc␥Rs (Fc␥RI, Fc␥RIIIA, and Fc␥RIV in mice; Fc␥RI and Fc␥RIIIA in humans), Fc␥RIIA does not associate with the FcR␥-subunit, and contains an ITAM in its intracytoplasmic domain. The Fc␥RIIA ITAM is, however, noncanonical, as it is several amino acids longer and kinked because of the presence of proline residues. 48 Fc␥RIIA has been considered less potent to activate cells than FcRs signaling through FcR␥-subunits as these subunits are expressed as dimers, thus providing 2 ITAMs per receptor. An elegant study using protein complementation 49 and crystallographic data 50 both suggest that Fc␥RIIA are expressed as noncovalent dimers. Thus, Fc␥RIIA and other activating Fc␥Rs have the same number of ITAMs when expressed at the cell membrane. Whereas both types of receptors have the ability to induce intracellular calcium concentration increase, 51 tyrosine phosphorylation events, 52 and mediator release from granules, 23, 27 only the FcR␥ ⌱⌻〈⌴ was reported to enable antigen presentation and cytokine secretion 13, 14 upon receptor crosslinking. The inability of Fc␥RIIA to induce cytokine secretion after engagement has been contradicted by reports on human skin-derived mast cells 27 or on human macrophages. 53 Here, we detected chemokine (KC and MIP-1␣) secretion by ex vivo alveolar macrophages, but failed to detect cytokine secretion by in vitro-derived murine mast cells (data not shown), after Fc␥RIIA engagement. Nevertheless, this latter stimulation led to the release of lipid mediators (LTC 4 , PGD 2 ), granular mediators (histamine, ␤hexosaminidase), calcium signaling, and to tyrosine phosphorylation of intracellular proteins. Among them, Syk, PLC␥1, Akt, Erk1/2, and SHIP1 were readily phosphorylated upon Fc␥RIIA engagement. These results correlate with previous reports showing that Syk and SHIP associate to Fc␥RIIA, are phosphorylated upon receptor aggregation, 29, 54 and that Fc␥RIIA requires PLC␥1 for calcium signaling. 14 Phosphorylation of most intracellular signaling proteins was, however, less prominent after Fc␥RIIA engagement than after Fc⑀RI engagement. Similar results were reported when comparing Fc␥RIIA with Fc␥RI downstream signaling. 14 Altogether, these data suggest that Fc␥RIIA enables cell activation through similar, although not identical, signaling pathways compared with those activated by FcR␥-associated FcRs. This may lead to differences in biologic outcome, in particular when considering cytokine production.
Finally, when considering its pattern of expression and its ability to activate myeloid cells, human Fc␥RIIA appears as a functional homolog of mouse Fc␥RIIIA. Noticeably, both receptors are the only activating Fc␥Rs expressed on mast cells, basophils, and eosinophils in humans and mice, respectively. Fc␥RIIA is, however, coexpressed in humans with inhibitory Fc␥RIIB on basophils (L. Cassard and F.J., unpublished data, 2011), and on some monocytes and rare neutrophils. 55 Because mouse and human Fc␥RIIB both inhibit cell activation by the same mechanism, 56 and because human Fc␥RIIA is coexpressed with mouse Fc␥RIIB in FcR␥ Ϫ/Ϫ IIA mice on basophils, monocytes, and neutrophils, we wondered if mouse Fc␥RIIB could negatively regulate human Fc␥RIIA-triggered PSA. We found that PSA was less profound in FcR␥ Ϫ/Ϫ IIA mice (expressing mFc␥RIIB) than in 3KOIIA (lacking mFc␥RIIB; supplemental Figure 3A ). Similar to mouse Fc␥RIIB, human Fc␥RIIB may therefore also negatively regulate Fc␥RIIAtriggered anaphylaxis in humans. In vivo, Fc␥RIIA demonstrated strong potential to activate myeloid cells and induce inflammatory and allergic pathologies in transgenic mice. Indeed, Fc␥RIIA engagement can activate neutrophils leading to nephritis 40 or anaphylactic shock (this paper and Jönsson et al 1 ). Fc␥RIIA engagement can also activate macrophages leading to rheumatoid arthritis, 39 thrombocytopenia, 17 lung inflammation, or anaphylactic shock and activate mast cells leading to PCA (this paper). Therefore, even though Fc␥RIIA may appear less efficient in vitro than other FcR␥-associated FcRs, its properties are sufficient for the induction of severe allergic, autoimmune and inflammatory pathologies in vivo. Targeting Fc␥RIIA with specific blocking molecules in inflammation and autoimmune/allergic reactions in humans might lead to similar inhibition as we reported recently for mouse Fc␥RIIIA in a murine model of rheumatoid arthritis, 57 in PSA and in ASA. 1 Supporting this assumption, we report here that blocking Fc␥RIIA protected transgenic mice from local and systemic anaphylaxis. Blocking Fc␥RIIA using divalent ligands (eg, mAb IV.3) to prevent allergic and autoimmune disease in humans, however, should not be envisioned, as we report here that high-doses of mAb IV.3 induced rather than prevented anaphylaxis. Small chemical entities, which prevent immune-complex binding to Fc␥RIIA, have proven efficient in a murine model of arthritis in Fc␥RIIA-transgenic mice, 20 and may not induce these adverse effects. In conclusion, blocking Fc␥RIIA might be a potential approach for various allergic diseases, including non-IgEmediated anaphylactic shocks that may be induced after Fc␥RIIA engagement on monocyte/macrophages and neutrophils.
